AU
UK
CA
NZ
IND
US
Predictive Oncology launched a new digital asset treasury strategy centered on the ATH token.
Eledon Pharmaceuticals (NASDAQ:ELDN) released its third quarter 2025 update, highlighting significant clinical, regulatory, and financial developments. Central to the announcement were the encouraging results from the Phase 2 BESTOW trial, which evaluated tegoprubart as a potential alternative to traditional immunosuppressive therapies in kidney transplantation. …
Trevi Therapeutics (NASDAQ:TRVI) has received a series of updates from research firms in recent days. D. Boral Capital reaffirmed its "buy" rating on the stock with a target price of $19.00, suggesting a potential upside from the stock's most recent close. This aligns with …
Aethlon Medical, Inc. (NASDAQ:AEMD)announced its financial results for the fiscal second quarter ended September 30, 2025. Consolidatedoperating expensestotaled USD 1.5 Mn, down 48% from USD 2.9 Mn in Q2 2024. The decrease was primarily due to lower payroll, general and administrative, and professional expenses.
Molecular Partners AG (NASDAQ:MOLN), a clinical-stage biotech developing DARPin therapeutics, presented new data on MP0712, its lead Radio-DARPin targeting DLL3, at the Targeted Radiopharmaceuticals Summit Europe 2025. The presentation included first human images and supporting mechanism of action data, illustrating targeted tumor delivery. MP0712 …
DBV Technologies (NASDAQ:DBVT), a clinical-stage biopharmaceutical company, confirmed the completion of the last patient visit in its Phase 3 VITESSE trial. The study is evaluating the VIASKIN® Peanut patch in peanut-allergic children aged 4–7 years. This double-blind, placebo-controlled trial marks the end of the …
INOVIO Pharmaceuticals, Inc. (NASDAQ:INO), a biotechnology company developing DNA medicines targeting HPV-related diseases, cancer, and infectious diseases, announced its plans to conduct a public offering of its common stock. All shares in the offering will be sold by the company, which will also grant …
Precision BioSciences, Inc. (NASDAQ:DTIL)reported new findings from its ongoing Phase 1 ELIMINATE-B study of PBGENE-HBV at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025. PBGENE-HBV is an in vivo gene editing therapy designed to target HBV cccDNA and …
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)released its financial results for Q3 2025 and shared an operational update. The US launch of EKTERLY® (sebetralstat) began on July 7, 2025. By October 31, 2025, the company had received 937 patient start forms and activated 423 unique prescribers.
Innate Pharma SA (NASDAQ:IPHA) announced that the U.S. Food and Drug Administration (FDA) has completed its review of the confirmatory Phase 3 protocol for lacutamab in cutaneous T-cell lymphomas (CTCL). The FDA had no further comments, allowing the trial to proceed.
Please wait processing your request...